Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02108600 · ClinicalTrials.gov registry record · Phase 2
Tocilizumab for Renal Graft Inflammation
A Phase 2 study of Late Complication From Kidney Transplant, sponsored by Flavio Vincenti.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT02108600: Completed Phase 2 study of Late Complication From Kidney Transplant, sponsored by Flavio Vincenti.
NCT02108600 is a Phase 2 study of Late Complication From Kidney Transplant that has completed, run by Flavio Vincenti. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02108600, a Phase 2 study of Late Complication From Kidney Transplant, has completed, sponsored by Flavio Vincenti.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized open label clinical trial in which 48 renal transplant recipients with inflammation in the 6 month allograft biopsy will either continue usual immunosuppression or receive monthly Actemra (Tocilizumab) infusions for 6 months in addition to usual immunosuppression.
Primary Outcome
Proportion of participants in each group who had a 1 point decrease in inflammation based on Banff scoring on renal allograft biopsy at 6 months compared to baseline. The Banff ti- score can be 0, 1, 2 or 3.
Conditions Studied
Interventions
- DRUG Tocilizumab
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-06 |
| Est. Completion | 2018-12-16 |
| Phase | Phase 2 |
What the finished NCT02108600 record still lists
NCT02108600 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Late Complication From Kidney Transplant appearing as the primary indexed condition, and to 1 intervention - of which Tocilizumab is the first listed.
NCT02108600 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02108600 about?
NCT02108600 is a clinical study titled "Tocilizumab for Renal Graft Inflammation". Randomized open label clinical trial in which 48 renal transplant recipients with inflammation in the 6 month allograft biopsy will either continue usual immunosuppression or receive monthly Actemra (Tocilizumab) infusions for 6 months in addition to usual immunosuppression.
What is the current status of trial NCT02108600?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2014-06. Estimated completion is 2018-12-16.
What conditions does trial NCT02108600 study?
This clinical trial studies the following conditions: Late Complication From Kidney Transplant.
What interventions are being tested in trial NCT02108600?
The interventions under investigation include: Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT02108600?
This trial is sponsored by Flavio Vincenti, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02108600 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02108600's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia